General objective
- Yo assess the overall effects of treatment with beta-3 adrenergic receptor agonists in adults with OAB by doing a systematic review and meta-analysis of all available RCTs.
- To compare the efficacy and safety of beta-3 adrenergic receptor agonists as an intervention for adult patients with OAB through assessing its effect on the symptoms of urgency, incontinence, nocturia and frequency by making the following comparisons:
- beta-3 adrenergic receptor agonists versus placebo or no treatment;
- beta-3 adrenergic receptor agonists versus conservative physical treatments (e.g. bladder training, urge suppression, pelvic floor muscle training).
- beta-3 adrenergic receptor agonists versus anticholinergic/antimuscarinic drugs (e.g. tolterodine, darifenacin, solifenacin, fesoterodine, oxybutynin, propiverine);
- beta-3 adrenergic receptor agonists versus intravesical Onabotulinumtoxin A injection;
- beta-3 adrenergic receptor agonists versus electrical stimulation (non-invasive or implanted);
- one dose regimen of a beta-3 adrenergic receptor agonist versus another;
- one frequency of administration of a beta-3 adrenergic receptor agonist versus another;
- one route of administration of a beta-3 adrenergic receptor agonist versus another;
- one type of beta-3 adrenergic receptor agonist versus another.
This is a protocol.